Curis (CRIS) to Release Earnings on Wednesday

Curis (NASDAQ:CRIS) is anticipated to release its results before the market opens on Wednesday, February 4th. Analysts expect Curis to post earnings of ($0.4325) per share and revenue of $3.2490 million for the quarter.

Curis (NASDAQ:CRIS) last announced its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.13. The firm had revenue of $3.18 million during the quarter, compared to the consensus estimate of $2.86 million. On average, analysts expect Curis to post $-7 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Curis Trading Up 3.3%

Shares of NASDAQ CRIS opened at $0.95 on Wednesday. The company has a market capitalization of $12.28 million, a price-to-earnings ratio of -0.26 and a beta of 3.00. The business has a 50 day simple moving average of $1.09 and a 200-day simple moving average of $1.44. Curis has a twelve month low of $0.77 and a twelve month high of $3.57.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curis in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Curis currently has a consensus rating of “Hold” and an average target price of $17.00.

Hedge Funds Weigh In On Curis

Several hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC grew its holdings in shares of Curis by 17.9% in the 3rd quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 8,973 shares during the last quarter. Maverick Capital Ltd. lifted its position in Curis by 7.8% in the 2nd quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock worth $1,472,000 after buying an additional 49,554 shares in the last quarter. Finally, Armistice Capital LLC boosted its position in Curis by 8.7% during the third quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock valued at $1,624,000 after purchasing an additional 78,265 shares during the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.